GRI Bio Announces Pricing Of $4M Public Offering; Potential Additional Gross Proceeds To The Co From The Series Warrants, If Fully Exercised On A Cash Basis, Will Be ~$8M
Portfolio Pulse from Benzinga Newsdesk
GRI Bio, Inc. (NASDAQ:GRI) announced the pricing of a $4M public offering, including Series C-1 and C-2 warrants. If fully exercised, the warrants could bring in an additional $8M. The offering is expected to close around June 28, 2024, with H.C. Wainwright & Co. as the exclusive placement agent.
June 27, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GRI Bio announced a $4M public offering with Series C-1 and C-2 warrants, potentially raising an additional $8M if fully exercised. The offering is expected to close around June 28, 2024.
The public offering and potential additional funds from the warrants could provide GRI Bio with significant capital to advance its pipeline, which is likely to be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100